Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / HK inno.N Corporation

Clinicaltrial registered6 Nov 2026

HK inno.N Corporation

6 Nov 2026: Trial registered · Efficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
6 Nov 2026
Title
Efficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD
Conditions
Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD)
Study Type
Observational
Status
Recruiting
Countries
South Korea
Country
South Korea
Reference
NCT07920679
Location
South Korea
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at HK inno.N Corporation

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for HK inno.N Corporation in our registers.

More from South Korea

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.